Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 22, 2025, by Heron Therapeutics, Inc., a Delaware corporation. The filing discloses the entry into a Material Definitive Agreement regarding the company's new corporate headquarters.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the new lease agreement:
- Monthly Base Rent: $614,550.50 for the first 12-month term.
- Rent Escalation: Base rent will increase by a certain percentage for each subsequent 12-month term.
- Operating Costs: The company is responsible for its proportionate share.
- Abatement: Base rent and estimated operating costs will be abated for a certain number of months following the Term Commencement Date.
Material Changes
The primary material change is the execution of an Office Lease Agreement dated August 22, 2025, with USEF HCG Fenton LLC. Key terms include:
- Location: 25 Fenton Main Street, Cary, North Carolina (approx. 16,837 rentable square feet).
- Lease Term: Approximately 111 months.
- Extension Option: One-time option to extend for 84 additional months.
- Right of First Refusal: One-time right to lease contiguous vacant space.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the standard lease obligations. The full terms of the lease will be available in the company's Quarterly Report on Form 10-Q for the period ending September 30, 2025.
Investor Verification Checklist
- Verify the exact "Term Commencement Date" to determine when rent payments begin.
- Confirm the specific percentage for rent increases in subsequent 12-month terms.
- Determine the exact duration of the rent and operating cost abatement period.
- Review the full lease agreement in the upcoming Form 10-Q for detailed covenants and termination clauses.